Skip to content
Home › 13F recaps › Q3 2026 › DXCM

Which funds bought or sold DXCM in Q3 2026?

Dexcom Inc. 5 funds bought, 3 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$1.1B.

Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)

PostLinkedIn
Who bought and who sold DXCM, by estimated dollars
◀ SoldBought ▶

Top 10 each side. NEW = opened a position, OUT = sold the whole position.

Bought (5)

FundChangeEst. $Now
Citadel
Quant & multi-strategy
Added+241.3%+$252M$357M
Renaissance
Quant & multi-strategy
Added+43.9%+$62M$202M
ExodusPoint
Quant & multi-strategy
Added+567.5%+$57M$67M
Legal & General
Asset manager
Added+7.7%+$17M$239M
PRIMECAP
Growth / crossover
Added+50.2%+$8M$25M

Sold (3)

FundChangeEst. $Now
AllianceBernstein
Asset manager
Trimmed-79.8%−$805M$204M
UBS
Bank & broker
Trimmed-58.6%−$307M$217M
Wellington
Asset manager
Trimmed-39.2%−$288M$447M

Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.

Most bought in Q3 2026 → · Most sold →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.